Welcome to Hmobio!Global leader in active molecules.
Find Your Distributors

Select Your Country or Region

 $ USD

For research purposes only. Not for human experiments
You are here:Home-Inhibitors & Agonists-Nuclear Receptor/Transcription Factor-PPAR

Request The Product List ofPPAR PPAR

PPARs (Peroxisome proliferator-activated receptors) are ligand-activated transcription factors of nuclear hormone receptor superfamily comprising of the following three subtypes: PPARα, PPARγ, and PPARβ/δ. PPARs play essential roles in the regulation of cellular differentiation, development, and metabolism (carbohydrate, lipid, protein), and tumorigenesis of higher organisms. All PPARs heterodimerize with the retinoid X receptor (RXR) and bind to specific regions on the DNA of target genes. Activation of PPAR-α reduces triglyceride level and is involved in regulation of energy homeostasis. Activation of PPAR-γ enhances glucose metabolism, whereas activation of PPAR-β/δ enhances fatty acids metabolism.

Cat. No. Product Name CAS No. Information
H9592

AZD-9574

 		2756333-39-6

AZD-9574 is a potent, blood-brain barrier (BBB) penetrant and PARP1 selective inhibitor. AZD9574 can be used for primary and secondary brain malignancies research.
H9579

Nesuparib

 		2055357-64-5

Nesuparib is a potent inhibitor of PARP. Nesuparib is useful for the research of neuropathic pain, neurodegenerative disease, and cardiovascular disease
H9539

Bocidelpar

 		2095128-20-2

Bocidelpar is a modulator of peroxisome proliferator-activated receptor delta (PPAR-δ). Bocidelpar improves mitochondrial biogenesis and function in Duchenne Muscular Dystrophy (DMD) muscle cells.
H9331

Ibrigampar

 		315224-26-1

Ibrigampar is a highly potent, non-TZD, selective peroxisome proliferator-activated receptor gamma (“PPAR-γ“) modulator (SPPARM); INT131 is a PPAR-γ partial agonist and potential therapeutic agent for the treatment of type 2 diabetes.
H9287

Atamparib

 		2381037-82-5

Atamparib is a potent, across species and orally active NAD+ competitive inhibitor of PARP7. RBN-2397 selectively binds to PARP7 and restores interferon (Type I) signaling. RBN-2397 has the potential for the study of advanced or metastatic solid tumors.
H9267

Darglitazonev

 		141200-24-0

Darglitazone (CP-86325) is a thiazolidinedione, is a potent, selective, and orally active PPAR-γ agonist. Darglitazone is effective in controlling blood glucose and lipid metabolism, and can be uesd in type II diabetes research.
H8894

Venadaparib

 		1681017-83-3

Venadaparib is a novel phthalazinone derivatives for inhibiting activity of the Poly(ADP-​riboside) polymerase.
H8808

Chiglitazar

 		743438-45-1

Chiglitazar is a potent and selective PPAR agonist potentially for the treatment of type 2 diabetes. Chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats. Chiglitazar showed transactivating activity in each PPARα, γ, and δ subtype and upregulated the expression of PPARα and/or PPARδ downstream genes involved in the key processes of lipid metabolism and thermogenesis.
H8807

Carfloglitazar

 		2213406-75-6

Carfloglitazar is a potent and selective PPAR agonist potentially for the treatment of type 2 diabetes. Chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats. Chiglitazar showed transactivating activity in each PPARα, γ, and δ subtype and upregulated the expression of PPARα and/or PPARδ downstream genes involved in the key processes of lipid metabolism and thermogenesis.
H5922

WY-14643

 		50892-23-4

A potent, selective PPARα agonist with EC50 of 0.63 uM; displays little or no activity for PPARγ and PPARδ (EC50=32 and >100 uM, respectively); modulates cellular redox status, represses NF-kappaB signaling, and reduces inflammatory cytokine production in mice.

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
© Copyright 2020 HmoBio. All Rights Reserved. Products are only for research use
沪ICP备2020027822号-1